A Monte Carlo simulation for modelling outcomes of AIDS treatment regimens

PharmacoEconomics

Volumn 20, Issue 4, 2002, Pages 215-224

  Richter, A ^a   Hauber, B ^a   Simpson, K ^b   Mauskopf, J A ^a   Yin, D ^c  

^a RTI HEALTH SOLUTIONS   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DATA BASE; DRUG COST; DRUG EFFICACY; EVALUATION; HEALTH CARE SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONTE CARLO METHOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW;

EID: 0036246896     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200220040-00001     Document Type: Review

References (37)

1. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
2. Antiretroviral therapy: Initial strategies
3. The cost-effectiveness of combination antiretroviral therapy in HIV disease
4. A Monte Carlo simulation of advanced HIV disease: Application to prevention of CMV infection
5. Current issues in Pneumocystis carinii pneumonia (PCP) prophylaxis in HIV: Using simulation modelling to inform clinical guidelines
6. Impact of drug non-compliance and the frequency of viral load testing on outcomes, costs, and patterns of therapy
7. Prediction of cost and outcomes for HIV patients monitored with viral load versus CD4 counts
8. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens
9. Ritonavir + saquinavir (RIT + SAQ) salvage therapy in antiretroviral-experienced patients
10. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS clinical trials group study 359
11. Virologic and immunologic consequences of discontinuing combination antiretroviral drug therapy in HIV-infected patients with detectable viremia
12. Immune restoration with antiretroviral therapies: Implications for clinical management
13. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naïve individual with HIV infection: Selection of thymidine analog regimen therapy (START I)
14. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus and prior antiretroviral therapy
15. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up
16. The efavirenz development team and the DMP 266-003 study team. Durable clinical anti-HIV activity and tolerability for efavirenz in combination with indinavir
17. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
18. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy
19. Antiretroviral clinical trials on the 50th anniversary of the randomized controlled clinical trial
20. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
21. Design and assessment of cost-effectiveness studies in AIDS populations
22. Combination therapy in eight developed countries: Events and costs of therapy with saquinavir, zalcitabine and zidovudine therapy in Australia, Canada, Germany, Italy, Spain, Switzerland, UK, and USA
23. Progressive CD4 depletion and death in zidovudine-treated patients
24. Factors associated with survival in human immunodeficiency virus-infected patients with very low CD4 counts
25. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy
26. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs
27. Health values of patients infected with human immunodeficiency virus
28. The natural history of HIV-1 infection: Staging classifications of disease